Iovance Biotherapeutics, Inc. (IOVA)
| Previous close | 11.71 |
| Open | 11.49 |
| Bid | 11.27 x 200 |
| Ask | 11.34 x 200 |
| Day's range | 11.16 - 11.58 |
| 52-week range | 3.21 - 18.33 |
| Volume | |
| Avg. volume | 8,978,879 |
| Market cap | 3.159B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.89 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.00 |
Insider Monkey20 Counties with the Highest Cancer Rates in the US
In this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact of cancer, head straight to the 5 Counties with the Highest Cancer Rates in the US. Confronting Cancer: Global Impact and Trends in […]
GlobeNewswireIovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline MelanomaSAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizuma
- GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new,
